ENGOT Phase I/II Clinical Trial Group

Mission Statement

 

  • We aim to accelerate the development of new therapies derived from a solid scientific rational for women with gynaecological cancer through European collaboration.

  • We aim at using the multidisciplinary expertise available within ENGOT to develop therapies via full spectrum clinical testing from first in human trials to randomised registration trials.

  • We aim at strengthening the scientific basis for late stage clinical testing through early clinical testing with strong integrated translational research.

 

Objectives

 

  • To develop a network of early phase trial centres and investigators within ENGOT to deliver early phase clinical trials with strong scientific rational.

  • To develop novel trial designs that allow efficient assessment of new compounds and make it feasible to also investigate rare histological and molecular subtypes.

  • To offer pharmaceutical companies a read-to-go, efficient structure and academic expertise for accelerated clinical development of their compounds in their pipeline

  • To deliver the most promising new compounds and therapeutic approaches to women with gynaecological cancer.

Up Coming Phase I/II Meeting

To be announced

You May Also Like

GCA6

GCA WORKSHOPS

Watch the Webcasts 

 

Read More

background

CLINICAL TRIALS

Latest Published Research

 

Read More

patient2

FOR PATIENTS

Key Insights

 

Read More

Athens_logo

ESGO 2019 Congress

ESGO 2019 Athen Congress

 

Read More